{"title":"Rising resistance: antibiotic choices for Helicobacter pylori infection","authors":"Kartika Afrida Fauzia, Vo Phuoc Tuan","doi":"10.1016/s2468-1253(23)00354-0","DOIUrl":"https://doi.org/10.1016/s2468-1253(23)00354-0","url":null,"abstract":"Asia is an area characterised by a notably elevated age-standardised rate of gastric cancer, 1 Sekiguchi M Oda I Matsuda T Saito Y Epidemiological trends and future perspectives of gastric cancer in Eastern Asia. Digestion. 2022; 103: 22-28 Crossref PubMed Scopus (31) Google Scholar exacerbated by a concomitantly high prevalence of Helicobacter pylori infection. 2 Hooi JKY Lai WY Ng WK et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017; 153: 420-429 Summary Full Text Full Text PDF PubMed Scopus (1688) Google Scholar Effective strategies to eradicate H pylori are therefore imperative. For these reasons, the systematic review and meta-analysis done by Tzu-Chan Hong and colleagues, 3 Hong T-C El-Omar E-M Kuo Y-T et al. Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023; (published online Nov 13.)https://doi.org/10.1016/S2468-1253(23)00281-9 PubMed Google Scholar in which the primary antibiotic resistance of H pylori was assessed in the Asia-Pacific region, has particular utility. Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: an updated systematic review and meta-analysisTreatment guidelines should be adapted in response to the rising primary resistance of key antibiotics for H pylori eradication. A global policy to control and monitor the antibiotic resistance of H pylori is urgently needed. Full-Text PDF","PeriodicalId":478628,"journal":{"name":"The Lancet Gastroenterology & Hepatology","volume":"113 3","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135714313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Research in Brief","authors":"Holly Baker","doi":"10.1016/s2468-1253(23)00287-x","DOIUrl":"https://doi.org/10.1016/s2468-1253(23)00287-x","url":null,"abstract":"Camrelizumab plus rivoceranib represents a new option for first-line treatment of unresectable or metastatic hepatocellular carcinoma, according to the CARES-310 phase 3 trial. Shukui Qin and colleagues randomly assigned patients who had not previously received systemic treatment to receive either intravenous camrelizumab 200 mg every 2 weeks plus oral rivoceranib 250 mg once daily (n=272) or oral sorafenib 400 mg twice daily (n=271). Median progression-free survival (PFS) was 5·6 months (95% CI 5·5–6·3) in the camrelizumab–rivoceranib group versus 3·7 months (2·8–3·7) in the sorafenib group (hazard ratio [HR] 0·52 [95% CI 0·41–0·65]; one-sided p<0·0001). Overall survival (interim analysis) was 22·1 months (95% CI 19·1–27·2) versus 15·2 months (95% CI 13·0–18·5), respectively (HR 0·62 [0·49–0·80]; one-sided p<0·0001). Grade 3 or worse treatment-related adverse events were more common in the camrelizumab–rivoceranib group than in the sorafenib group (219 [81%] vs 145 [54%]); the most common was hypertension (102 [38%] vs 40 [15%]).","PeriodicalId":478628,"journal":{"name":"The Lancet Gastroenterology & Hepatology","volume":"107 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135219625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Research in Brief","authors":"Holly Baker","doi":"10.1016/s2468-1253(23)00245-5","DOIUrl":"https://doi.org/10.1016/s2468-1253(23)00245-5","url":null,"abstract":"Bulevirtide shows promise in patients with hepatitis D virus (HDV), according to early results from the MYR 301 clinical trial. Heiner Wedemeyer and colleagues randomly assigned patients with chronic HDV with or without compensated cirrhosis to receive either bulevirtide 2 mg (n=49) or bulevirtide 10 mg (n=50) daily for 144 weeks, or no treatment for 48 weeks followed by bulevirtide 10 mg daily for 96 weeks (control group; n=51). At week 48, a combined response of undetectable HDV RNA or an HDV RNA concentration that had decreased by at least 2 log10 IU per mL from baseline, and normalisation of alanine aminotransferase concentration, was achieved in 22 (45%) patients in the 2 mg group and 24 (48%) in the 10 mg group compared with one (2%) in the control group (p<0·001 for each doses vs control). HDV RNA was undetectable in none of the patients in the control group, in six (12%) patients in the 2 mg group, and in ten (20%) patients in the 10 mg group (p=0·41 for difference between bulevirtide groups). Headache, pruritus, and fatigue were the most common adverse events that were more frequently observed with bulevirtide than with control.","PeriodicalId":478628,"journal":{"name":"The Lancet Gastroenterology & Hepatology","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136236414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Research in Brief","authors":"Holly Baker","doi":"10.1016/s2468-1253(23)00200-5","DOIUrl":"https://doi.org/10.1016/s2468-1253(23)00200-5","url":null,"abstract":"Upadacitinib shows promise as induction and maintenance therapy for Crohn's disease, according to a phase 3 clinical programme consisting of two induction trials (U-EXCEL and U-EXCEED) and one maintenance trial (U-ENDURE). In the induction trials, Edward V Loftus Jr and colleagues randomly assigned patients with moderate-to-severe Crohn's disease to receive either upadacitinib 45 mg (350 patients in U-EXCEL and 324 in U-EXCEED) or placebo (176 patients in U-EXCEL and 171 in U-EXCEED) once daily for 12 weeks. Patients with clinical response to upadacitinib were then randomly assigned to receive upadacitinib 15 mg (n=169), upadacitinib 30 mg (n=168), or placebo (n=165) once daily for 52 weeks (U-ENDURE). A significantly higher proportion of patients in the upadacitinib 45 mg groups achieved clinical remission compared with placebo (in U-EXCEL, 49·5% vs 29·1%; in U-EXCEED, 38·9% vs 21·1%). In U-ENDURE, clinical remission was achieved in 37·3% of the upadacitinib 15 mg group and 47·6% of the upadacitinib 30 mg group compared with 15·1% for placebo (p<0·001). Herpes zoster infections occurred more frequently in the 45 mg and 30 mg upadacitinib groups than in the respective placebo groups, and hepatic disorders and neutropenia were more frequent in the 30 mg upadacitinib group than in the other maintenance groups.","PeriodicalId":478628,"journal":{"name":"The Lancet Gastroenterology & Hepatology","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135771280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Research in Brief","authors":"Holly Baker","doi":"10.1016/s2468-1253(23)00163-2","DOIUrl":"https://doi.org/10.1016/s2468-1253(23)00163-2","url":null,"abstract":"Bariatric–metabolic surgery improves non-alcoholic steatohepatitis (NASH) in people with obesity and should be considered as an alternative to lifestyle intervention plus best medical care, according to the BRAVES trial. Ornella Verrastro and colleagues randomly assigned patients with obesity and histologically confirmed NASH, irrespective of their type 2 diabetes status, to receive either lifestyle modification plus best medical care (n=96), Roux-en-Y gastric bypass (n=96), or sleeve gastrectomy (n=96). In the intention-to-treat analysis, at 1-year follow-up, the primary endpoint of histological resolution of NASH without worsening of fibrosis was met by 54 (56%) patients in the Roux-en-Y gastric bypass group and 55 (57%) in the sleeve gastrectomy group compared with 15 (16%) in the lifestyle modification group—significantly higher with bariatric–metabolic surgery than with lifestyle modification (p<0·0001). Severe adverse events occurred in ten (6%) patients across the surgery groups; however, all events were resolved with medical or endoscopic management.","PeriodicalId":478628,"journal":{"name":"The Lancet Gastroenterology & Hepatology","volume":"51 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135154701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Research in Brief","authors":"Holly Baker","doi":"10.1016/s2468-1253(23)00119-x","DOIUrl":"https://doi.org/10.1016/s2468-1253(23)00119-x","url":null,"abstract":"Vedolizumab is an option for the treatment of chronic pouchitis, according to the results of a phase 4 trial reported by Simon Travis and colleagues. Patients with chronic pouchitis after having undergone restorative proctocolectomy with ileal pouch–anal anastomosis for ulcerative colitis were randomly assigned to receive either intravenous vedolizumab 300 mg (n=51) or placebo (n=51) on day 1 and at weeks 2, 6, 14, 22, and 30, alongside ciprofloxacin from weeks 1 to 4. At week 14, the primary endpoint of remission defined by modified Pouchitis Disease Activity Index (mPDAI) was observed in 16 (31%) of 51 patients in the vedolizumab group compared with five (10%) of 51 patients in the placebo group (difference, 21 percentage points, 95% CI 5–38; p=0·01). Vedolizumab also showed benefit over placebo in terms of mPDAI-defined remission at week 34, mPDAI-defined response at week 14 and 34, and PDAI-defined remission at week 14 and week 34. A similar number of serious adverse events occurred across groups: three (6%) in the vedolizumab group and four (8%) for placebo.","PeriodicalId":478628,"journal":{"name":"The Lancet Gastroenterology & Hepatology","volume":"103 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135575433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Research in Brief","authors":"Holly Baker","doi":"10.1016/s2468-1253(23)00076-6","DOIUrl":"https://doi.org/10.1016/s2468-1253(23)00076-6","url":null,"abstract":"Etrasimod, a selective modulator of the S1P receptor, provides a new oral option for induction and maintenance therapy for patients with moderately to severely active ulcerative colitis, according to the results of two phase 3 trials. William Sandborn and colleagues randomly assigned patients to receive either etrasimod 2 mg or placebo once-daily for a 12-week induction period in the ELEVATE UC 12 trial and for a 12-week induction period followed by a 40-week maintenance period in the ELEVATE UC 52 trial. In ELEVATE UC 52, 74 (27%) of 274 patients in the etrasimod group achieved clinical remission at the end of the 12-week induction period versus ten (7%) of 135 patients in the placebo group (p<0·0001). Similar proportions of patients were in clinical remission at 52 weeks (88 [32%] vs nine [7%]; p<0·0001). In ELEVATE UC 12, 55 (25%) of 222 patients in the etrasimod group were in clinical remission versus 17 (15%) of 112 patients in the placebo group at 12 weeks (p=0·026). The most common adverse events included anaemia, headache, and worsening or flare of ulcerative colitis.","PeriodicalId":478628,"journal":{"name":"The Lancet Gastroenterology & Hepatology","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135917658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}